Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELATIVITY-127 subcutaneous versus intravenous nivolumab + relatlimab in untreated unresectable or metastatic melanoma
2022-500967-11-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of nivolumab, relatlimab and ENHANZE in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Pharmacokinetic non-inferiority of subcutaneous versus intravenous nivolumab and Pharmacokinetic non-inferiority of subcutaneous versus intravenous relatlimab. Planned start Jul 2023; status: authorised.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2022-500967-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500967-11-00.